[A25-44] Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2025
Project no.:
A25-44
Commission:
Commission awarded on 31.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with von Hippel-Lindau disease who require therapy for associated localized renal cell carcinoma, central nervous system haemangioblastomas or pancreatic neuroendocrine tumours, and for whom localized procedures are unsuitable
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-44
| Project no. | Title | Status |
|---|---|---|
| A25-45 | Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |